Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 9, 2004. The report details specific corporate actions regarding directors' interests in ordinary shares and a share buyback program executed on November 9, 2004.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on share transaction data:
- Share Buyback Price: 1,183.70 pence per share.
- Shares Purchased: 650,000 ordinary shares.
- Total Treasury Shares: 51,328,000 shares held following the transaction.
- Shares in Issue: 5,884,980,578 shares (excluding treasury shares).
Material Changes
The primary material changes reported are:
- Share Repurchase: The company utilized shareholder authority granted at the May 17, 2004 Annual General Meeting to purchase 650,000 shares for treasury.
- Directors' Interests: Two separate transfers occurred from the GlaxoSmithKline Employee Trust (GSK Trust) to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- On November 5, 2004: 410,826 shares transferred.
- On November 8, 2004: 2,846 shares transferred.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total number of shares held in treasury (51,328,000) against subsequent filings to monitor capital return strategies.
- Confirm the impact of the 650,000 share buyback on the company's total issued share count.
- Review the GSK Trust disclosures to understand the extent of director interests relative to the broader employee base.